Gene expression profiling of tissues revealed that PD-1 and PD-L1 expressions, biomarkers of inflammation (CD3 and CD8), and inflammatory gene signatures (CD274, CD8A, LAG3, STAT1) tended to be associated with improved survival and responses of HCC patients treated with anti-PD1 antibody [108]. Here, CD8A is linked to hepatocellular carcinoma.